Nasus Pharma Ltd. NSRX
3.48
0.00
0.00%
as of 25 Sep
- Market cap
- $40.8M
- P/E
- —
Follow NSRX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
0.12 | 0.06 | 2.24 | 8.77 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
251.32% | 401.10% | 0.00% | 0.00% | |
Debt/Equity |
(0.56) | (0.59) | 0.00 | 0.00 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | — | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(0.66) | (0.43) | (4.93) | (6.04) | |
Working Capital |
(3.47) | (4.66) | 2.69 | 10.91 | |
Capital Expenditures |
0.00 | — | (0.01) | 0.00 | |
Net Current Asset Value |
(3.47) | (4.66) | 2.62 | 10.86 | |
| Other line items | |||||
Quick Ratio |
0.08 | 0.05 | 0.60 | 5.63 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Average Payables |
— | — | — | 0.50 | |
Average Assets |
— | — | — | 6.45 | |
Average Common Equity |
— | — | — | 3.60 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates